Proteinase-activated Receptor 2 Promotes Cancer Cell Migration Through RNA Methylation-mediated Repression of MiR-125b

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2015 Sep 11

PMID 26354435

Citations 39

Authors

Lan Yang

Yiming Ma

Wenxiao Han

Weiwei Li

Liang Cui

Xinhua Zhao

Yantao Tian

Zhixiang Zhou

Wengong Wang

Hongying Wang

Affiliations

Soon will be listed here.

Abstract

Proteinase activated-receptor 2 (PAR2) participates in cancer metastasis promoted by serine proteinases. The current study aimed to test the molecular mechanism by which PAR2 promotes cancer cell migration. In different cancer cells, activation of PAR2 by activating peptide (PAR2-AP) dramatically increased cell migration, whereas knock down of PAR2 inhibited cellular motility. The PAR2 activation also repressed miR-125b expression while miR-125b mimic successfully blocked PAR2-induced cell migration. Moreover, Grb associated-binding protein 2 (Gab2) was identified as a novel target gene of miR-125b and it mediated PAR2-induced cell migration. The correlation of PAR2 with miR-125b and Gab2 was further supported by the findings obtained from human colorectal carcinoma specimens. Remarkably, knock down of NOP2/Sun domain family, member 2 (NSun2), a RNA methyltransferase, blocked the reduction in miR-125b induced by PAR2. Furthermore, PAR2 activation increased the level of N(6)-methyladenosine (m(6)A)-containing pre-miR-125b in NSun2-dependent manner. Taken together, our results demonstrated that miR-125b mediates PAR2-induced cancer cell migration by targeting Gab2 and that NSun2-dependent RNA methylation contributes to the down-regulation of miR-125b by PAR2 signaling. These findings suggest a novel epigenetic mechanism by which microenvironment regulates cancer cell migration by altering miRNA expression.

Citing Articles

Trends and frontiers of RNA methylation in cancer over the past 10 years: a bibliometric and visual analysis.

Liu B, Gao X, Piao Y Front Genet. 2024; 15:1461386.

PMID: 39473440 PMC: 11519982. DOI: 10.3389/fgene.2024.1461386.

RNA 5-methylcytosine marks mitochondrial double-stranded RNAs for degradation and cytosolic release.

Kim S, Tan S, Ku J, Widowati T, Ku D, Lee K Mol Cell. 2024; 84(15):2935-2948.e7.

PMID: 39019044 PMC: 11316625. DOI: 10.1016/j.molcel.2024.06.023.

RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy.

Liu W, Zheng S, Li T, Fei Y, Wang C, Zhang S Signal Transduct Target Ther. 2024; 9(1):70.

PMID: 38531882 PMC: 10966055. DOI: 10.1038/s41392-024-01777-5.

Development and validation of an immune-related gene prognostic index for lung adenocarcinoma.

Liu Z, Lei Y, Shen J, Zhao G, Wang X, Wang Y J Thorac Dis. 2023; 15(11):6205-6227.

PMID: 38090291 PMC: 10713328. DOI: 10.21037/jtd-23-1374.

NSUN2-mediated m5C modification of HBV RNA positively regulates HBV replication.

Feng J, Xu T, He M, Li J, Yao P, Ma C PLoS Pathog. 2023; 19(12):e1011808.

PMID: 38048324 PMC: 10721180. DOI: 10.1371/journal.ppat.1011808.

References

Bera A, VenkataSubbaRao K, Manoharan M, Hill P, Freeman J . A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer. PLoS One. 2014; 9(9):e106343. PMC: 4153643. DOI: 10.1371/journal.pone.0106343. View

Zhou W, Fong M, Min Y, Somlo G, Liu L, Palomares M . Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25(4):501-15. PMC: 4016197. DOI: 10.1016/j.ccr.2014.03.007. View

Melillo R, Guarino V, Avilla E, Galdiero M, Liotti F, Prevete N . Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010; 29(47):6203-15. DOI: 10.1038/onc.2010.348. View

Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F . Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol. 2006; 169(1):268-78. PMC: 1698759. DOI: 10.2353/ajpath.2006.050841. View

Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S . Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol. 2005; 89(2):79-85. DOI: 10.1002/jso.20197. View

Wilson S, Gallagher S, Warpeha K, Hawthorne S . Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate. 2004; 60(2):168-74. DOI: 10.1002/pros.20047. View

Ohta T, Shimizu K, Yi S, Takamura H, Amaya K, Kitagawa H . Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int J Oncol. 2003; 23(1):61-6. View

Versteeg H, Schaffner F, Kerver M, Ellies L, Andrade-Gordon P, Mueller B . Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res. 2008; 68(17):7219-27. PMC: 2596617. DOI: 10.1158/0008-5472.CAN-08-0419. View

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2006; 282(2):1479-86. DOI: 10.1074/jbc.M609383200. View

10.

Matsumura T, Sugimachi K, Takahashi Y, Uchi R, Sawada G, Ueda M . Clinical significance of GAB2, a scaffolding/docking protein acting downstream of EGFR in human colorectal cancer. Ann Surg Oncol. 2014; 21 Suppl 4:S743-9. DOI: 10.1245/s10434-014-3889-x. View

11.

Tsai K, Kao H, Chen H, Chen S, Lin W . Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics. 2009; 4(8):587-92. DOI: 10.4161/epi.4.8.10230. View

12.

Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia R . Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene. 2009; 28(34):3047-57. PMC: 2733915. DOI: 10.1038/onc.2009.163. View

13.

Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K . Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat. 2010; 127(2):549-54. DOI: 10.1007/s10549-010-1244-x. View

14.

Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M . Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol. 2005; 36(6):676-85. DOI: 10.1016/j.humpath.2005.04.008. View

15.

Schaffner F, Yokota N, Ruf W . Tissue factor proangiogenic signaling in cancer progression. Thromb Res. 2012; 129 Suppl 1:S127-31. DOI: 10.1016/S0049-3848(12)70032-4. View

16.

Wohrle F, Daly R, Brummer T . Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal. 2009; 7:22. PMC: 2747914. DOI: 10.1186/1478-811X-7-22. View

17.

Huang L, Lin J, Yu Y, Zhang M, Wang H, Zheng M . Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012; 7(3):e33762. PMC: 3306296. DOI: 10.1371/journal.pone.0033762. View

18.

Nishibori M, Mori S, Takahashi H . Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. J Pharmacol Sci. 2005; 97(1):25-30. DOI: 10.1254/jphs.fmj04005x5. View

19.

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

20.

Zhang X, Liu Z, Yi J, Tang H, Xing J, Yu M . The tRNA methyltransferase NSun2 stabilizes p16INK⁴ mRNA by methylating the 3'-untranslated region of p16. Nat Commun. 2012; 3:712. PMC: 3509206. DOI: 10.1038/ncomms1692. View